Former head of Pfizer Ignite joins self-replicating RNA startup Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 19 December, 2025

Share your perspective. Endpoints is fielding the next Biopharma Sentiment Index (BPSI), a three-minute survey that distills thousands of industry views into a quarterly benchmark. It’s one of the clearest snapshots of how people inside biopharma see the year ahead. Add your voice today.

presented by Strength in rar­i­ty: Why biotech spon­sors are dou­bling down on rare on­col­o­gy con­sor­tia

SPOTLIGHT In Focus The Endpoints winners and losers list: Who was up and who was down in 2025 •  Watch: Our 2025 winners and losers list — on Post-Hoc Live What Endpoints will be talking about at JPM: Major CEOs, top investors, China and more

news China's biotech sector is advancing faster than thought, US commission says Catalent handed two Form 483s, including for Sarepta gene therapy site Peer Review Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes over UK committee demands ‘much-needed clarity’ on UK-US pharma trade deal

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic

ENDPOINTS PHARMA FDA puts partial hold on Daiichi and Merck's I-Dxd lung cancer study after deaths FutureHouse spinoff Edison raises $70M seed for its AI-doing-science platform Moderna lands CEPI as new backer for its pandemic flu program Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

in case you missed it 1. Takeda's $4B immunology drug achieves first Phase 3 successes 2. Lilly’s obesity pill is the first oral GLP-1 to show its worth in the maintenance setting 3. After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset 4. Exclusive: Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis